Patent 10336824 was granted and assigned to CytomX Therapeutics on July, 2019 by the United States Patent and Trademark Office.
The invention relates generally to antibodies that bind programmed death ligand 1 (PDL1), activatable antibodies that specifically bind to PDL1 and methods of making and using these anti-PDL1 antibodies and anti-PDL1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.